You are here: Industry Insights > COVID-19

News List

Aalto Bio Reagents announces it is supplying reagents for the manufacturing of tens of millions of COVID-19 antibody tests per month prnewswire
June 10, 2020
Aalto Bio Reagents Ltd. announced that its Sars-CoV-2 n-s1-S2 antigens, Lysis buffers and Viral transport media are part of assays that are being run in Europe and the U.S. ...
Relief Therapeutics, NeuroRx Begin RLF-100 Study for COVID-19 Associated ARDS americanpharmaceuticalreview
June 10, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced treatment of the first patients with RLF-100 at the University of Miami Miller School of Medicine, FL.
Eleva's Drug Candidate Examined for Use in COVID-19 Treatment americanpharmaceuticalreview
June 10, 2020
Eleva is exploring the potential of one of its drug candidates for first-in-line therapy of COVID-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of COVID-19.
EMA recieves CMA application for remdesivir as a COVID-19 treatment europeanpharmaceuticalreview
June 10, 2020
The European Medicines Agency (EMA) said its assessment of the conditional marketing authorisation (CMA) application will be performed under a reduced timeframe, with a decision potentially delivered in weeks.
Daiichi Sankyo to develop Nafamostat inhalation therapy for Covid-19 pharmaceutical-technology
June 10, 2020
Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.
AstraZeneca licences Covid-19 antibody candidates from VU pharmaceutical-technology
June 10, 2020
AstraZeneca has licensed six coronavirus-neutralising antibody candidates from Vanderbilt University (VU) in the US, with plans to advance two into clinical development to prevent and treat Covid-19.
Abbott India Q4FY20 performance hit by COVID 19 impact: ICICI Securities expresspharma
June 10, 2020
“We have reduced our revenue and EPS estimates for FY21E-FY22E by 4-5 per cent and 12-14 per cent to factor COVID-19 impact and lower other income,” commented the capital market company on the pharma company’s financial performance for the quarter.
Lilly and Junshi Biosciences Initiate Phase I COVID-19 Trials contractpharma
June 10, 2020
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
SwiftScale Manufactures COVID-19 Antibody Candidate contractpharma
June 10, 2020
Uses rapid biologics manufacturing technology to accelerate development of treatments.
A2A Pharmaceuticals Collaborates with Laxai Life Sciences contractpharma
June 10, 2020
Will co-develop SARS-CoV-2 main proteases inhibitors for the treatment of COVID-19.